Skip to main content
Erschienen in: Journal of Gastroenterology 1/2021

22.10.2020 | Original Article—Liver, Pancreas, and Biliary Tract

The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy

verfasst von: Koji Tezuka, Yukiyasu Okamura, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Katsuhiko Uesaka

Erschienen in: Journal of Gastroenterology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Familial pancreatic cancer (FPC) is defined as a family in which at least two first-degree relatives have pancreatic cancer (PC). The prognostic significance of PC in an FPC family after surgery is not fully understood.

Methods

This was a retrospective study of 427 patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma between January 2008 and December 2016. PC patients who also had at least one first-degree relative with PC were defined as FPC patients. The associations between recurrence and clinicopathological characteristics were analyzed for both FPC and non-FPC patients.

Results

FPC patients accounted for 31 of the 427 (7.3%) patients. Recurrence occurred in 72.1% of the total cohort and in 87.1% of the 31 FPC patients. Multivariate analysis showed that being an FPC patient was an independent predictor for relapse-free survival (RFS) (hazard ratio [HR] 1.52, P = 0.038). Although univariate analysis revealed that being an FPC patient was significantly associated with poorer overall survival (OS) (P < 0.001), multivariate analysis showed that being an FPC patient was not an independent predictor for OS (P = 0.164). Dichotomization of the 427 patients into those who received (n = 317: 17 FPC and 300 non-FPC patients) and did not receive (n = 110: 14 FPC and 96 non-FPC patients) adjuvant chemotherapy revealed that being an FPC patient was an independent predictor for RFS (HR 2.50, P < 0.001) and OS (HR 2.30, P = 0.003) only for patients who received adjuvant chemotherapy.

Conclusions

This study has shown that being an FPC patient is a significant prognostic indicator for PC patients who undergo resection and receive adjuvant chemotherapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. CrossRef Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. CrossRef
2.
Zurück zum Zitat Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. CrossRef Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. CrossRef
3.
Zurück zum Zitat Werner J, Combs SE, Springfeld C, et al. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323–33. CrossRef Werner J, Combs SE, Springfeld C, et al. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323–33. CrossRef
4.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2017. National Cancer Institute. Bethesda, MD based on November 2019 SEER data submission, posted to the SEER web site, Apr 2020. https://seer.cancer.gov/csr/1975_2017/. Accessed 25 Apr 2020. Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2017. National Cancer Institute. Bethesda, MD based on November 2019 SEER data submission, posted to the SEER web site, Apr 2020. https://​seer.​cancer.​gov/​csr/​1975_​2017/​. Accessed 25 Apr 2020.
5.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57. CrossRef Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57. CrossRef
6.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81. CrossRef Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81. CrossRef
7.
Zurück zum Zitat Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. CrossRef Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. CrossRef
8.
Zurück zum Zitat Raufi AG, Manji GA, Chabot JA, et al. Neoadjuvant treatment for pancreatic cancer. Semin Oncol. 2019;46:19–27. CrossRef Raufi AG, Manji GA, Chabot JA, et al. Neoadjuvant treatment for pancreatic cancer. Semin Oncol. 2019;46:19–27. CrossRef
10.
Zurück zum Zitat Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43:548–53. CrossRef Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43:548–53. CrossRef
11.
Zurück zum Zitat Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. CrossRef Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. CrossRef
12.
Zurück zum Zitat Wada K, Takaori K, Traverso LW, et al. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci. 2013;20:557–66. CrossRef Wada K, Takaori K, Traverso LW, et al. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci. 2013;20:557–66. CrossRef
14.
Zurück zum Zitat Mintziras I, Bartsch DK. Progress report: familial pancreatic cancer. Fam Cancer. 2019;18:359–62. CrossRef Mintziras I, Bartsch DK. Progress report: familial pancreatic cancer. Fam Cancer. 2019;18:359–62. CrossRef
15.
Zurück zum Zitat Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–8. CrossRef Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–8. CrossRef
16.
Zurück zum Zitat Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7–17. CrossRef Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7–17. CrossRef
17.
Zurück zum Zitat Humphris JL, Johns AL, Simpson SH, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120:3669–75. CrossRef Humphris JL, Johns AL, Simpson SH, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120:3669–75. CrossRef
18.
Zurück zum Zitat Barton JG, Schnelldorfer T, Lohse CM, et al. Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. J Gastrointest Surg. 2011;15:836–42. CrossRef Barton JG, Schnelldorfer T, Lohse CM, et al. Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. J Gastrointest Surg. 2011;15:836–42. CrossRef
19.
Zurück zum Zitat Norris AL, Roberts NJ, Jones S, et al. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Fam Cancer. 2015;14:95–103. CrossRef Norris AL, Roberts NJ, Jones S, et al. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Fam Cancer. 2015;14:95–103. CrossRef
20.
Zurück zum Zitat Brierley JD, Gospondarowicz MK, Wittekind C. International Union Against Cancer. TNM classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017. Brierley JD, Gospondarowicz MK, Wittekind C. International Union Against Cancer. TNM classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.
21.
Zurück zum Zitat Yamada M, Sugiura T, Okamura Y, et al. Microscopic venous invasion in pancreatic cancer. Ann Surg Oncol. 2018;25:1043–51. CrossRef Yamada M, Sugiura T, Okamura Y, et al. Microscopic venous invasion in pancreatic cancer. Ann Surg Oncol. 2018;25:1043–51. CrossRef
22.
Zurück zum Zitat Sugiura T, Uesaka K, Mihara K, et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery. 2013;154:1078–86. CrossRef Sugiura T, Uesaka K, Mihara K, et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery. 2013;154:1078–86. CrossRef
23.
Zurück zum Zitat James TA, Sheldon DG, Rajput A, et al. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer. 2004;101:2722–6. CrossRef James TA, Sheldon DG, Rajput A, et al. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer. 2004;101:2722–6. CrossRef
24.
Zurück zum Zitat Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004;110:902–6. CrossRef Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004;110:902–6. CrossRef
25.
Zurück zum Zitat Takai E, Yachida S, Shimizu K, et al. Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget. 2016;7:74227–35. CrossRef Takai E, Yachida S, Shimizu K, et al. Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget. 2016;7:74227–35. CrossRef
26.
Zurück zum Zitat Ji J, Forsti A, Sundquist J, et al. Survival in familial pancreatic cancer. Pancreatology. 2008;8:252–6. CrossRef Ji J, Forsti A, Sundquist J, et al. Survival in familial pancreatic cancer. Pancreatology. 2008;8:252–6. CrossRef
27.
Zurück zum Zitat Yeo TP, Hruban RH, Brody J, et al. Assessment of “gene-environment” interaction in cases of familial and sporadic pancreatic cancer. J Gastrointest Surg. 2009;13:1487–94. CrossRef Yeo TP, Hruban RH, Brody J, et al. Assessment of “gene-environment” interaction in cases of familial and sporadic pancreatic cancer. J Gastrointest Surg. 2009;13:1487–94. CrossRef
28.
Zurück zum Zitat Roberts NJ, Norris AL, Petersen GM, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6:166–75. CrossRef Roberts NJ, Norris AL, Petersen GM, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6:166–75. CrossRef
29.
Zurück zum Zitat Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333–9. CrossRef Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333–9. CrossRef
30.
Zurück zum Zitat Blair AB, Groot VP, Gemenetzis G, et al. BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226:630–7. CrossRef Blair AB, Groot VP, Gemenetzis G, et al. BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226:630–7. CrossRef
31.
Zurück zum Zitat Kondo T, Kanai M, Kou T, et al. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget. 2018;9:19817–25. CrossRef Kondo T, Kanai M, Kou T, et al. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget. 2018;9:19817–25. CrossRef
32.
Zurück zum Zitat Brandt A, Bermejo JL, Sundquist J, et al. Age of onset in familial cancer. Ann Oncol. 2008;19:2084–8. CrossRef Brandt A, Bermejo JL, Sundquist J, et al. Age of onset in familial cancer. Ann Oncol. 2008;19:2084–8. CrossRef
33.
Zurück zum Zitat McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55:252–8. CrossRef McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55:252–8. CrossRef
34.
Zurück zum Zitat Singhi AD, Ishida H, Ali SZ, et al. A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology. 2015;15:387–91. CrossRef Singhi AD, Ishida H, Ali SZ, et al. A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology. 2015;15:387–91. CrossRef
35.
Zurück zum Zitat Mavros MN, Xu L, Maqsood H, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22:4382–91. CrossRef Mavros MN, Xu L, Maqsood H, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22:4382–91. CrossRef
Metadaten
Titel
The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy
verfasst von
Koji Tezuka
Yukiyasu Okamura
Teiichi Sugiura
Takaaki Ito
Yusuke Yamamoto
Ryo Ashida
Katsuhisa Ohgi
Katsuhiko Uesaka
Publikationsdatum
22.10.2020
Verlag
Springer Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 1/2021
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01730-7

Weitere Artikel der Ausgabe 1/2021

Journal of Gastroenterology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.